-
-
In this issue: Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
Without fanfare, the FDA approved oral tranexamic acid tablets (Lysteda), the first non-hormonal product cleared to treat heavy menstrual bleeding in the United States.
-
Fibrates: Generally safe, but do they improve outcomes?; Safety of testosterone replacement; Glucosamine and low back pain; Effects of allopurinol upon exercise in patients with angina; Is obesity a factor in asthma?; A new tool for treatment of plantar warts
-
-
A physician in new York notified relevant county and state public health authorities in August 2009, of a patient from Rochester with suspected dengue, subsequently confirmed by CDC, whose only travel had been to Key West, FL. Confirmation at the CDC included both serum antibody testing and detection of dengue virus serotype 1 in cerebrospinal fluid.
-
Cryptococcal infection has taken another new twist. For years before the HIV epidemic, infection with C. neoformans mostly occurred in immunosuppressed individuals who also had some defined zoonotic exposure, often to birds or pigeons.
-
-
Ivermectin is a well-known anti-parasitic medication that has been used for years, with little toxicity to humans.
-
Several years ago, two different publications appeared showing that prolonged incubation of blood cultures beyond the initial five-day protocol for patients with suspected fastidious bacterial endocarditis did not yield significant additional pathogens with today's modern blood-culture media and automated methods.